Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galicaftor - AbbVie/Galapagos NV

Next Previous
Drug Profile

Galicaftor - AbbVie/Galapagos NV

Alternative Names: ABBV 2222; GLPG-2222; SION-2222

Latest Information Update: 10 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
  • Developer AbbVie; Galapagos NV
  • Class Amides; Antifibrotics; Benzoic acids; Chromans; Cyclopropanes; Dioxolanes; Fluorinated hydrocarbons; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 26 Jun 2025 Sionna Therapeutics plans a phase I trial for Cystic fibrosis (In volunteers, In adults, Combination therapy) in Australia (PO, Capsule), in July 2025 (NCT07035990)
  • 06 Jun 2025 Pharmacodynamics data from a preclinical study in Cystic fibrosis released in Sionna Therapeutics
  • 20 Mar 2025 Sionna Therapeutics plans a phase I MAD trial for Cystic fibrosis (In volunteers, Combination therapy) in the second half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top